Gain Therapeutics GANX 深 滬
等待開盤 09-25 09:30:00 美东时间
1.84
0.000
0.00%
華盛通- 最 高1.855
- 今 開1.84
- 成交量 40.57万股
- 最 低 1.79
- 昨 收 1.84
- 總市值 8030.43万
- 52周最高 4.34
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 1.53
- 委 比 37.52%
- 總股本 4364.36万
- 歷史最高 17.93
- 量 比 1.00
- 振 幅 3.53%
- 歷史最低 0.89
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Gain Therapeutics, Inc. announced that its CEO, Gene Mack, will participate in the ROTH Healthcare Opportunities Conference on September 29, 2026, discussing "Frontiers in Neuroscience." The company is advancing its lead drug candidate, rexaceract, for Parkinson's disease and other conditions, using its Magellan platform to develop innovative therapies.
09-17 11:00
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
Gain Therapeutics, Inc. announced that its President and CEO, Gene Mack, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 14-16, 2026. An on-demand company presentation will be available starting September 11, 2026, at 7:00 a.m. ET, accessible via the provided links. Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation...
08-25 11:00
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share from the same period last year.
08-11 19:30
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Gain Therapeutics provided an update on its lead drug candidate, rexaceract, for Parkinson’s disease. The Phase 1b study showed safety, tolerability, and early signs of efficacy, with reductions in biomarkers like GluSph and clinical benefits observed. The company received IND authorization and plans to start a Phase 2 study in Q3 2026. Additionally, a second candidate, GT-04686, is advancing in preclinical development. The company also announced...
07-16 11:00
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
07-01 19:46
美股夜盘 | 707 Cayman Holdings涨62.04%，Abivax SA Sponsored ADR涨31.05%
GMEX ROBOTICS CORPORATION Class A涨-29.32%；Concentrix Corporation涨-22.83%；Decoy Therapeutics Inc.涨-16.37%
06-30 08:05
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
Gain Therapeutics ( ($GANX) ) has provided an announcement. On June 29, 2026, G...
06-30 04:51
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Gain Therapeutics' GT-02287 has received FDA IND authorization, enabling Phase 2 clinical development in the U.S. for Parkinson's disease. Positive Phase 1 results showed target engagement, safety, and tolerability, with anecdotal improvements in symptoms. GT-02287, developed using Gain's Magellan AI platform, is the first allosteric modulator to achieve IND clearance. Phase 2 is expected to begin in 3Q26, involving sites in the U.S., Australia, ...
06-29 20:05
